Xin Lang Cai Jing·2025-10-31 04:14Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a total revenue of 215.072 billion yuan for Q3 2025, ranking first among disclosed peers, with a year-on-year increase of 2.60% [1] - The net profit attributable to shareholders reached 5.147 billion yuan, also ranking first among peers, reflecting a year-on-year increase of 26.96% [1] - The company achieved a net cash inflow from operating activities of 2.350 billion yuan, ranking second among peers [1] Financial Performance - The latest debt-to-asset ratio is 62.14%, a decrease of 0.53 percentage points from the previous quarter and 0.69 percentage points from the same period last year [3] - The gross profit margin stands at 10.42% [3] - The return on equity (ROE) is 6.79%, ranking 10th among peers, with an increase of 1.07 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 1.39 yuan, ranking 4th among peers, with a year-on-year increase of 27.52% [3] - The total asset turnover ratio is 0.94 times, ranking 11th among peers [3] - The inventory turnover ratio is 4.77 times, ranking 14th among peers [3] Shareholder Structure - The number of shareholders is 92,900, with the top ten shareholders holding 3.283 billion shares, accounting for 88.52% of the total share capital [3] - The largest shareholder is HKSCC NOMINEES LIMITED, holding 2.471 billion shares [3] - Other significant shareholders include Shanghai Pharmaceuticals (Group) Co., Ltd. and Yunnan Baiyao Group Co., Ltd., holding 1.930 billion and 1.790 billion shares respectively [3]